Product Information
TACROLIMUS 0.03% OINTMENT is a generic product labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., priced at $0.9983 per GM under NDC 00168041760. Its NADAC has been published 607 times since Feb 18, 2015.
FDA first approved this application on Sep 9, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.3 mg/g
NDC
00168041760
Classification
Generic
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
TACROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA200744FDA Approved
9/9/2014
TE Code
AB
On Market Since
9/9/2014
Pharmacological Classes
Price Statistics
The NADAC for TACROLIMUS 0.03% OINTMENT has been published 607 times since Feb 18, 2015, and over the history we have for it it has declined 84.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9983 per GM |
|---|---|
| All-time high | $6.5168 (Jun 10, 2015) |
| All-time low | $0.5582 (May 22, 2024) |
| 52-week high | $0.9983 |
| 52-week low | $0.7651 |
| Median price | $3.3858 |
| Average price | $3.2223 |
| Largest weekly change | +50.4% (Mar 22, 2023) |
| Weeks tracked | 607 |
| Tracking since | Feb 18, 2015 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tacrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TACROLIMUS 0.03% OINTMENT?
The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 0.03% OINTMENT, manufactured by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., is $0.9983 per GM (NDC 00168041760), effective Sep 30, 2026.
How has the price of TACROLIMUS 0.03% OINTMENT changed over time?
Over the history we have for it, the NADAC for TACROLIMUS 0.03% OINTMENT has declined 84.2%. It has been tracked across 607 weekly CMS publications since Feb 18, 2015.
What are the highest and lowest recorded NADAC prices for TACROLIMUS 0.03% OINTMENT?
Since Feb 18, 2015, the NADAC for TACROLIMUS 0.03% OINTMENT has ranged from a low of $0.5582 (May 22, 2024) to a high of $6.5168 (Jun 10, 2015), with a median of $3.3858 per GM.
Are there cheaper alternatives to TACROLIMUS 0.03% OINTMENT?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TACROLIMUS 0.03% OINTMENT, is $0.8878 per GM — about 11% below TACROLIMUS 0.03% OINTMENT.
Who manufactures TACROLIMUS 0.03% OINTMENT?
TACROLIMUS 0.03% OINTMENT (NDC 00168041760) is labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., and CMS classifies it as a generic product.